Delving into Portal Fibroblast Ablation to Treat Cholestatic Fibrosis
Time: 11:45 am
day: Conference Day 2 Track 1 AM
Details:
- Activated Portal Fibroblasts (aPFs) and Hepatic Stellate Cells (aHSCs) contribute to populations of myofibroblasts in response to cholestatic liver fibrosis. Ablation of myofibroblasts with cellspecific immunotoxins or CART cells has been suggested as a potential immunotherapy of liver fibrosis
- Ablation of aPFs suppresses cholestatic liver fibrosis without causing mortality or distress in mice and can be used for treatment of cholestatic liver fibrosis
- Ablation of HSCs suppresses liver fibrosis but affects hepatocyte proliferation causing a defect in liver regeneration. Total ablation of HSC population cannot be used for anti-fibrotic therapy
